Aardvark Therapeutics Faces Scrutiny as FDA Holds Back Key Drug Candidate, Stock Plummets#United_States#San_Francisco#FDA_Hold#Aardvark_Therapeutics#ARD-101
Aardvark Therapeutics Faces Scrutiny as FDA Holds Back Key Drug Candidate, Stock Plummets
Aardvark Therapeutics has faced another setback as the FDA places a hold on its main drug candidate, leading to a significant drop in stock value. Investors are urged to remain vigilant.
third-news.com
July 30, 2026 at 5:31 PM
Aardvark Therapeutics Faces Scrutiny as FDA Holds Back Key Drug Candidate, Stock Plummets#United_States#San_Francisco#FDA_Hold#Aardvark_Therapeutics#ARD-101
Concerns Raised Over Regenxbio's Disclosure Before FDA's Surprising Hold on Clinical Programs#USA#New_York#FDA_Hold#Regenxbio_Inc.#RGNX
Concerns Raised Over Regenxbio's Disclosure Before FDA's Surprising Hold on Clinical Programs
Levi & Korsinsky, LLP investigates Regenxbio Inc. amid questions regarding the transparency of investor information before regulatory setbacks in their clinical trials.
third-news.com
January 29, 2026 at 11:17 PM
Concerns Raised Over Regenxbio's Disclosure Before FDA's Surprising Hold on Clinical Programs#USA#New_York#FDA_Hold#Regenxbio_Inc.#RGNX
Investor Alert: Pomerantz Law Firm Reviews Allegations Against Gilead Sciences, Inc.#USA#New_York#Pomerantz_LLP#FDA_Hold#Gilead_Sciences
Investor Alert: Pomerantz Law Firm Reviews Allegations Against Gilead Sciences, Inc.
Pomerantz LLP is initiating an investigation into Gilead Sciences for possible securities fraud. Investors urged to contact the firm for guidance.
third-news.com
July 17, 2025 at 2:44 PM
Investor Alert: Pomerantz Law Firm Reviews Allegations Against Gilead Sciences, Inc.#USA#New_York#Pomerantz_LLP#FDA_Hold#Gilead_Sciences
Pomerantz Law Firm Investigates Potential Shareholder Claims Against PepGen Inc. Amid FDA Concerns#United_States#New_York#Pomerantz_LLP#PepGen_Inc.#FDA_Hold
Pomerantz Law Firm Investigates Potential Shareholder Claims Against PepGen Inc. Amid FDA Concerns
Pomerantz LLP is probing potential claims from PepGen Inc. investors following an FDA clinical hold notice, impacting share prices significantly.
third-news.com
December 27, 2024 at 9:03 PM
Pomerantz Law Firm Investigates Potential Shareholder Claims Against PepGen Inc. Amid FDA Concerns#United_States#New_York#Pomerantz_LLP#PepGen_Inc.#FDA_Hold